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Mechanical VentilationAbstract Objective: The purpose of our study was to examine patients hospitalized with CAP
association between abnormal platelet count and levels of paCO2 and ICU admission and 30 days
mortality.
Methods: This retrospective study was conducted on 173 patients diagnosed as CAP admitted to
Mansoura University Hospital. Arterial blood gases and CBC were obtained at admission with the
measurement of platelet count and paCO2. Data were collected and analyzed.
Results: Patients with abnormal platelet count thrombocytopenia (19%) or thrombocytosis
(28%) had a higher length of hospital stay, were more in the need for ICU admission, more use
of mechanical ventilation invasive or non invasive more 30 days mortality rate with more associa-
tion of pulmonary complication like pleural effusion.
Both groups of hypercapnia (13%) and hypocapnia (42%) had a higher ICU admission and
higher 30 day mortality rate.
Conclusion: Patients with abnormality in platelet count and levels of paCO2 were associated with
an increase in ICU admission and higher 30 day mortality.
They should be considered for inclusion in future severity criteria to identify patients who are in
need for a higher level of care.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Community-acquired pneumonia (CAP) represents one of the
most common causes of ICU admission [1]. Prior investiga-
tions of CAP in the ICU have shown that the requirement
for mechanical ventilation is associated with increased mortal-
ity compared with non-ventilated patients [2–8].Platelets havebeen increasingly recognized as an important component of
innate and adaptive immunities [9–11].
Platelet response in antimicrobial host defense is similar, in
many ways, to the leukocyte response: both cell types contain
antimicrobial peptides that act against a broad range of patho-
gens. After platelets and neutrophils are activated, they accumu-
late at the site of infection to produce a direct contact between
their antimicrobial peptides and invading bacteria. Leukocytes
need to phagocytize bacteria to achieve interaction with intra-
cellular peptides; platelets can also internalize microorganisms
into phagosomelike vacuoles, enhancing pathogen clearance.rculosis.
454 H.M.S. Samaha, A.R. ElsaidAntimicrobial peptides fromboth cells exert a rapid, potent, and
direct antimicrobial effect that contributes to limiting the
infection [12].
Clinicians have always evaluated the degree of leukocytosis
in patients with pneumonia as an indication of systemic inﬂam-
matory response and severity of disease. Thrombocytopenia is
also a recognized marker of poor outcomes in patients with
pneumonia, due to the association of low platelet counts with
disseminated intravascular coagulation and severe sepsis [13].
Hypoxemic respiratory failure is well recognized as a prog-
nostic marker in different severity-of-illness scores to predict
poor clinical outcomes in hospitalized patients with CAP [14].
By contrast, ventilatory abnormalities reﬂected by an alter-
ation in PaCO2 have not been considered a poor prognostic
marker unless arterial pH changes are observed [15–17].
PaCO2 is widely accepted as an indicator of ventilator ade-
quacy. Abnormally high levels may indicate severe respiratory
fatigue and impending cardiopulmonary arrest [18].
We hypothesized that an abnormal platelet count may be
an important marker to assess severity of disease in patients
with CAP. The primary objective of this study was to investi-
gate the association of platelet count at the time of hospitaliza-
tion with mortality at 30 days in patients with CAP. The
secondary study objective was to examine the association
between abnormal PaCO2 and the need for invasive mechani-
cal ventilation, ICU admission, and 30-day mortality in
patients hospitalized with CAP.
Materials and methods
Study design and patient data
This was a retrospective cohort study of 173 patients admitted
with CAP to the Mansoura University Chest Department
between June 2010 and March 2013.
Patients enrolled were a part of the community-acquired
pneumonia. Clinical and laboratory data were collected for
each patient. These include a total of 36 variables regarding
patient’s demographic, co-morbidity, physical examination,
laboratory, and chest radiographic ﬁndings.
Collected data were used to estimate patient’s CAP severity
using the pneumonia severity index (PSI) and CRB-65 (confu-
sion, respiratory rate, blood pressure, 65 years of age and
older). We excluded patients with previous use of oral corticos-
teroids (?10 mg prednisone equivalent per day for at least
2 weeks); other immunosuppressive therapy; active solid or
hematologic neoplasms; HIV infection; active TB; hematologic
disease involving platelets and/or leukocytes, such as essential
thrombocytosis or myelodysplastic syndrome; and patients
hospitalized within the preceding 21 days due to chronic
obstructive pulmonary disease.
Study deﬁnitions
CAP was deﬁned as the presence of a new pulmonary inﬁltrate
on the chest radiograph at the time of hospitalization asso-
ciated with at least one of the following: (1) new or increased
cough, (2) an abnormal temperature (<35.6 C or 37.8 C),
(3) an abnormal serum leukocyte count (leukocytosis, left shift,
or leukopenia deﬁned by local laboratory values). Hypotensionwas deﬁned as a systolic blood pressure, <90 mm Hg or diasto-
lic blood pressure, <60 mm Hg. Alteration of gas exchange
was deﬁned as, PaCO2 values from the arterial blood gas mea-
sured in the ﬁrst 24 h of admission with CAP, the patients were
stratiﬁed into 3 groups: normal PaCO2 (35–45 mm Hg),
hypocapnic (PaCO2 6 35 mm Hg), and hypercapnic
(PaCO2 > 45 mm Hg).
Thrombocytopenia and thrombocytosis were deﬁned as
platelet counts 6100,000/L or >400,000/L, respectively.
Signiﬁcant leukopenia and leukocytosis were deﬁned here as
WBC counts of 64000 and >25,000 respectively.
The study outcome, 30-days mortality, was deﬁned as death
by any cause during the period of 30 days after hospital
admission.
Statistical analysis
Categorical variables were described as frequencies and
percentages and compared with x2 or ﬁsher exact test when
appropriate.
Continuous variables were expressed as mean ± SD and
compared between groups using one way analysis of variance,
for data not normally distributed.
Data were processed with the SPSS (Statistical Package for
Social Science) version (16).
The level of signiﬁcance.
p< 0.05 signiﬁcant.
p< 0.01 highly signiﬁcant.
p< 0.001 very highly signiﬁcant.
Results
During the study period, we evaluated 173 patients (94 males
(54%) and 79 females (46%)) with community acquired pneu-
monia who met inclusion criteria and in whom the platelet
count was taken at admission was available (see Tables 1 and 2).
33 patients (19%) were with thrombocytopenia (group I),
49 patients (28%) with thrombocytosis (group III) and 91
patients (53%) with normal platelet (group II).
All group patients’ age and sex matched without a signiﬁ-
cant difference.
There was no difference between groups in antibiotic receiv-
ing prior admission, active smoking history, the presence of co-
morbidity like heart failure, renal failure, liver failure and other
chronic illnesses like diabetes mellitus and neurological disease.
There was no signiﬁcant difference between the studied
group as regards the leukocytic count and heamatocrit value.
Patients with thrombocytosis had a higher heart rate at the
admission.
Patient with thrombocytosis and thrombocytopenia were
more in need for I.C.U admission and more in need for invasive
mechanical ventilation as p value between groups less than
0.001.
The mortality rate within 30 days of hospital admission and
length of hospital stay were higher in patients with throm-
bocytosis and thrombocytopenia than in patients with normal
platelet count, and p value less than 0.01.
Table 1 Characteristics of study patients at admission divided into 3 groups according to levels of platelet.
Group I N = 33 (19%) Group II N = 91 (53%) Group III N = 49 (28%)
Sex
Male 16 (48%) 51 (56%) 27 (55%) p> 0.05
Female 17 (52%) 40 (44%) 22 (45%)
Age 48 ± 1.5 42 ± 1.5 44 ± 1.9 p> 0.05
Length of hospital stay 10.5 ± 5.2 4.6 ± 1.6 10.9 ± 5 p< 0.001
Antibiotic prior admission 8 (24%) 41 (45%) 20 (40%) p> 0.05
Active smoking 8 (24%) 32 (35%) 13 (27%) p> 0.05
Heart failure 9 (27%) 23 (25%) 13 (26%) p> 0.05
Renal failure 8 (24%) 20 (22%) 10 (20%) p> 0.05
Liver failure 3 (1%) 13 (14%) 5 (10%) p> 0.05
Diabetes mellitus 10 (30%) 35 (38%) 20 (41%) p> 0.05
Neurological disease 2 (06%) 14 (15%) 11 (22%) p> 0.05
Respiratory rate 21(64%) 57 (63%) 35 (71%) p> 0.05
Heart rate 21 (64%) 58 (64%) 41 (84%) p< 0.05
Shock 17 (51%) 39 (43%) 29 (59%) p> 0.05
Temperature > 39 17 (52%) 40 (44%) 22 (45%) p> 0.05
Leukocytic count
Leukopenia 14 (42%) 17 (19%) 13 (27%) p> 0.05
Leukocytosis 6 (18%) 20 (22%) 10 (20%)
Normal 13 (40%) 54 (59%) 26 (53%)
Hematocrit value 7 (21%) 32 (35%) 20 (41%) p> 0.05
Pao2 24 (73%) 56 (62%) 33 (67%) p> 0.05
Na level 10 (30%) 30 (33%) 16 (33%) p> 0.05
Mental state 11 (33%) 27 (29%) 16 (32%) p> 0.05
ICU 31 (94% 64 (70%) 43 (88%) p< 0.001
Non invasive MV 16 (48%) 37 (41%) 16 (33%) p> 0.05
Invasive MV 15 (45%) 17 (19%) 24 (49%) p< 0.001
30 days mortality 8 (24%) 9 (1%) 14 (29%) p< 0.01
Pneumothorax 7 (21%) 18 (20%) 11 (22%) p> 0.05
Pleural eﬀusion 18 (55%) 31 (34%) 24 (49%) p< 0.05
Empyema 6 (18%) 14 (15%) 10 (20%) p> 0.05
Lung abscess 5 (15%) 11 (12%) 6 (12%) p> 0.05
Chest X-ray
Alveolar 5 (15%) 19 (21%) 13 (26%) p> 0.05
Interstitial 6 (18%) 25 (27%) 3 (6%)
Cavitation 9 (27%) 19 (21%) 19 (39%)
Multilobar 13 (40%) 28 (31%) 14 (29%)
CRB-65 2, 3, 4 19 (58%) 31 (34%) 31 (63%) p< 0.001
PSI class VI, V 25 (76%) 45 (49%) 37 (76%) p< 0.001
Table 2 Relation between the leukocytic count and 30 day mortality and length of hospital stay.
Group I N = 44 (25%) Group II N = 93 (54%) Group III N = 36 (21%)
30 days mortality 10 (22%) 14 (15%) 7 (19%) p> 0.05
Length of hospital stay 9.5 ± 5.2 7.1 ± 3.7 6.1 ± 3 p> 0.05
Predictors of CAP prognosis 455There was no signiﬁcant difference between studied groups
as regards the levels of paO2, Na levels and mental state.
There was no association between leukocytic count and pla-
telet count.
There was no signiﬁcant relation between the leukocytic
count and length of hospital stay and 30 days mortality.
Patientwithpulmonary complication like pleural effusionwas
higher in patients with thrombocytopenia than thrombocytosis
or normal platelet count patients. p value less than 0.05.
There was no difference between groups in the occurrence
of lung abscess, empyema or pneumothorax.
There was no signiﬁcant difference between groups in the
chest X-ray presentation P values were more than 0.05, whilepatients with thrombocytosis showed higher incidence of
cavitation.
Patients with thrombocytosis and thrombocytopenia had
higher PSI and CRB-65 scores at admission than patients with
normal platelet count.
As regards the levels of paCO2, the distribution among the
group was 73 patients (42%) with hypocapnia (paCO2
< 35 mm Hg) Group I*, 87 patients (50%) with normal
paCO2 (35–45 mm Hg) Group II* and 13 patients (8%) with
hypercapnia paCO2 (>45 mm Hg) Group III*.
Table 3 showed demographic characteristics of the studied
group. Patients with abnormal levels of paCO2 higher or lower
were more likely to have liver diseases, diabetes mellitus and
456 H.M.S. Samaha, A.R. Elsaidneurological disease, there was a high signiﬁcant difference
between studied groups regarding p values.
There was a signiﬁcant difference between the studied
group regarding body temperature above 38 C and
hyponatreamia.
As regards clinical outcomes over all 30 day mortality was
higher in patients with hypercapnia and hypocapnia compared
with the reference group with normal paCO2 (54%, 18% and
13% respectively) with p value < 0.001.
Both groups (hypercapnic and hypocanic) patients had sig-
niﬁcantly higher ICU admission and more in need for invasive
mechanical ventilation.
Patients with hypercapnic and hypocapnic were more liable
to the occurrence of pneumothorax as a complication of pneu-
monia, but there was no signiﬁcant difference between the
studied groups as regards the lung abscess, pleural effusion
and empyema.
Patients with abnormal paCO2 had higher PSI and CRB-65
scores at admission than patients with normocapnia.
There was no signiﬁcant difference between studied groups
regarding the length of hospital stay.Table 3 Characteristics of study patients at admission divided into
Group I* N= 73(42%) Group
Sex
Male 39 (53%) 50 (57%
Female 34 (47%) 37 (43%
Age 43 ± 1.2 45 ± 1.
Length of hospital stay 6 ± 3.2 8.2 ± 4
Antibiotic prior admission 34 (47%) 28 (32%
Active smoking 23 (32%) 28 (32%
Heart failure 14 (19%) 25 (29%
Renal failure 17 (23%) 17 (20%
Liver failure 15 (21%) 2 (2%)
Diabetes mellitus 34 (47%) 21 (24%
Neurological disease 10 (6%) 11 (13%
Respiratory rate 45 (62%) 59 (68%
Heart rate 47 (64%) 64 (74%
Shock 31 (42%) 25 (29%
Temperature 23 (32%) 43 (49%
Leukocytic count
Leukopenia 16 (22%) 22 (25%
Leukocytosis 15 (21%) 18 (21%
Normal 42 (57%) 47 (54%
Hematocrit value 31 (42%) 24 (28%
PaO2 54 (74%) 52 (60%
Na level 23 (32%) 31 (36%
Mental state 24 (33%) 21 (24%
ICU 61 (84%) 64 (74%
Non invasive MV 32 (44%) 37 (43%
Invasive MV 24 (33%) 21 (24%
30 days mortality 13 (18%) 11 (13%
Pneumothorax 22 (30%) 10 (11%
Pleural eﬀusion 30 (41%) 39 (45%
Empyema 13 (18%) 13 (15%
Lung abscess 6 (8%) 12 (14%
Chest X-ray
Alveolar 12 (16%) 25 (29%
Interstitial 11 (15%) 19 (22%
Cavitation 22 (31%) 22 (25%
Multilobar 28 (38%) 21 (24%
CRB-65 2, 3, 4 36 (49%) 33 (38%
PSI class VI, V 49 (67%) 47 (54%Patient with abnormality in paCO2 had more liability to
multilobar affection in chest X-ray without a signiﬁcant differ-
ence between studied groups.Discussion
The main ﬁndings of our study were as follows: that patients at
the time of hospitalization, abnormalities in platelet count are
better predictors of clinical outcomes in patients with CAP, as
follows
1. Patients with thrombocytosis and thrombocytopenia had a
higher 30 day mortality rate, more length of hospital stay,
more in need of ICU care, more in need for mechanical ven-
tilation invasive or non invasive and higher PSI andCRB-65.
2. As regards the pulmonary complication of pneumonia
pleural effusion was high in patients with thrombocytope-
nia with a signiﬁcant difference, while empyema was high
in patients with thrombocytosis without a signiﬁcant
difference.3 groups according to the levels of PaCO2.
II* N = 87 (50%) Group III* N = 13 (8%)
) 5 (38%) p> 0.05
) 8 (62%)
8 43 ± 2.2 p> 0.05
.1 7.9 ± 5 p> 0.05
) 7 (54%) p> 0.05
) 2 (15%) p> 0.05
) 6 (46%) p> 0.05
) 4 (31%) p> 0.05
4 (31%) p< 0.001
) 10 (77%) p< 0.001
) 6 (46%) p< 0.01
) 9 (69%) p> 0.05
) 9 (69%) p> 0.05
) 6 (46%) p> 0.05
) 4 (31%) p< 0.01
) 6 (46%) p> 0.05
) 3 (23%)
) 4 (31%)
) 4 (31%) p > 0.05
) 9 (69%) p> 0.05
) 2 (15%) p< 0.001
) 9 (69%) p< 0.01
) 13 (100%) p< 0.05
) 0 (0%) p< 0.01
) 11 (85%) p< 0.001
) 7 (54%) p< 0.001
) 4 (31%) p< 0.05
) 4 (31%) p> 0.05
) 4 (31%) p> 0.05
) 4 (31%) p> 0.05




) 12 (92%) p< 0.001
) 11 (85%) p< 0.01
Predictors of CAP prognosis 457Two prior studies, both in pediatric patients, reported an
association between thrombocytosis and poor outcomes in
patients with CAP [19,20]. The ﬁrst study reported that pneu-
monia in children with thrombocytosis seemed to have a more
severe and protracted course, whereas the second study sug-
gested that thrombocytosis was associated with a higher likeli-
hood of empyema. Compared with patients with normal
platelet counts, both the thrombocytopenia and thrombocyto-
sis groups presented with a worse prognosis but apparently for
different reasons:
This ﬁnding was in agreement with Prina et al. [21] who
concluded that thrombocytosis in patients with CAP asso-
ciated with poor outcomes, complicated pleural effusion and
empyema. The presence of thrombocytosis in CAP should
encourage ruling out respiratory complication and could be
considered for severity evaluation.
Mirsaeidi et al. [22] analyzed 500 patients with CAP, of
whom 65 (13%) presented thrombocytosis and 27 (5%) pre-
sented thrombocytopenia. These authors reported that both
patients with thrombocytopenia and those with thrombocyto-
sis had a signiﬁcantly higher mortality and that platelet count
was a better predictor of outcome than an abnormal leukocyte
count. However, the cause of mortality, complications, etiol-
ogy, and systemic inﬂammatory response were not analyzed
and the population studied included elderly patients with
cancer.
A possible explanation of why patients with thrombocyto-
sis had a poor outcome would be the higher rate of empyema
and complicated pleural effusion. In the literature, these types
of complications have been associated with a longer length of
hospital stay, treatment failure, and higher mortality.
According to our results, we suggest that platelet count
should be monitored in patients with CAP: thrombocytopenia
or thrombocytosis requires awareness of septic complications
and hemodynamic alterations, clinicians should pay attention
to local respiratory complications, such as pleural effusion
and empyema.
An important limitation of the study includes the fact the
investigation was conducted at a single center, the absence of
the cause of mortality, searching for the causative organism,
link between platelet count and inﬂammatory marker .We take
platelet at the admission serial measurement of platelet count
during hospitalization that could differentiate between tran-
sient event and sustained derangement in platelet count, we
did not evaluate possible difference in the functional activity
of platelet among the groups.
The main ﬁndings of our study are that patients hospital-
ized with CAP with abnormal paCO2 levels (hypercapnia or
hypocapnia) at the clinical presentation to the hospital were
more likely to die within 30 days of admission and require
ICU care when compared with those with normal paCO2.
This suggests that PaCO2 may play an important role in the
clinical outcomes in hospitalized patients with CAP.
A recent meta-analysis suggests that these severity score sys-
tems are not accurate to predict ICU admission [23]. These
scores include several demographic, co-morbid conditions,
physiologic, laboratory or radiologic variables, but none con-
sider paCO2 levels as criteria of severity. In addition, recent
new severity scores, such as SCAP [24] or SMART-COP [25],
have included low arterial pH as criteria, but paCO2 has not
been used as a predictive variable. It is well known that the levelsof paCO2 determine arterial pH value, but often pH values can
be compensated by bicarbonate levels, especially in patientswith
chronic disease, and may not reﬂect an abnormal paCO2 value.
Our results suggest that abnormal paCO2 levels should be
considered in severity of illness scores and require further
validation.
Both hypocapnia and hypercapnia are independently asso-
ciated with a greater tendency toward respiratory failure.
Hypocapnia can cause or aggravate cellular ischemia by induc-
ing a leftward shift in the oxyhemoglobin dissociation curve
and reducing oxygen delivery to tissues [26].
In respiratory disorders such as pneumonia, hypocapnia
can worsen ventilation–perfusion matching and gas exchange
in the lung via a number of mechanisms, including bron-
choconstriction, reduction in collateral ventilation, reduction
in parenchymal compliance, and attenuation of hypoxic pul-
monary vasoconstriction and increased intrapulmonary shunt-
ing [27]. Additionally, hypercapnia can increase sympathetic
neural drive, cardiac output, heart rate, and systemic and pul-
monary BP [28]. In patients with respiratory disorders, mainly
associated with hypoxemia, hypercapnia can increase pul-
monary vascular resistance, enhance hypoxic vasoconstriction,
mediate large airway constriction, impair contractility of vas-
cular smooth muscles, and limit gas exchange [29–31].We used
the decision of ICU admission as the gold standard, because
this reﬂected the actual clinical practice. ICU admission is an
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